![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
January 30, 2026
The co-chairs reflect on last year's key research advances and highlight priorities for 2026
January 30, 2026
This phase 3 clinical trial is evaluating a less intensive treatment approach for older adults with early-stage melanoma
January 30, 2026
The new objective is to identify biomarkers associated with malignant risk in pancreatic cysts, requiring current participants to reconsent
January 30, 2026
10 cancer research discoveries in 2025 by ECOG-ACRIN and PrECOG that captured attention across the scientific and patient advocacy communities
January 30, 2026
This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments
January 30, 2026
The latest research in breast cancer, geriatric oncology, leukemia, NCI-MATCH, and symptom management
January 30, 2026
Timely updates on research leaders, presentations at medical meetings and more